GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kura Oncology Inc (NAS:KURA) » Definitions » Interest Coverage

Kura Oncology (Kura Oncology) Interest Coverage : 0 (At Loss) (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Kura Oncology Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Kura Oncology's Operating Income for the three months ended in Mar. 2024 was $-54.45 Mil. Kura Oncology's Interest Expense for the three months ended in Mar. 2024 was $-0.40 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Kura Oncology's Interest Coverage or its related term are showing as below:


KURA's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 148.11
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Kura Oncology Interest Coverage Historical Data

The historical data trend for Kura Oncology's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Kura Oncology Interest Coverage Chart

Kura Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kura Oncology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kura Oncology's Interest Coverage

For the Biotechnology subindustry, Kura Oncology's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kura Oncology's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kura Oncology's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Kura Oncology's Interest Coverage falls into.



Kura Oncology Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kura Oncology's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Kura Oncology's Interest Expense was $-1.55 Mil. Its Operating Income was $-165.80 Mil. And its Long-Term Debt & Capital Lease Obligation was $15.69 Mil.

Kura Oncology did not have earnings to cover the interest expense.

Kura Oncology's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, Kura Oncology's Interest Expense was $-0.40 Mil. Its Operating Income was $-54.45 Mil. And its Long-Term Debt & Capital Lease Obligation was $15.61 Mil.

Kura Oncology did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Kura Oncology  (NAS:KURA) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Kura Oncology Interest Coverage Related Terms

Thank you for viewing the detailed overview of Kura Oncology's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Kura Oncology (Kura Oncology) Business Description

Traded in Other Exchanges
Address
12730 High Bluff Drive, Suite 400, San Diego, CA, USA, 92130
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States.
Executives
Brian T. Powl officer: Chief Commercial Officer C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131
Thomas Malley director C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Thomas James Doyle officer: SVP, Finance & Accounting C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Kirsten Flowers officer: Chief Commercial Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Kathleen Ford officer: Chief Operating Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Stephen Dale officer: Chief Medical Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Teresa Brophy Bair officer: Chief Legal Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Helen Louise Collins director TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Carol Schafer director 42 WHITE STREET, FOURTH FLOOR, NEW YORK NY 10013
Troy Edward Wilson director, officer: President and CEO C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Marc Grasso officer: CFO, CBO C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO CA 92121
Bridget A Martell officer: Acting Chief Medical Officer C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
James Basta officer: Chief Legal Officer C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK RD, SUITE 220, SAN DIEGO CA 92121
Diane L. Parks director 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Antonio Gualberto officer: Chief Medical Officer 245 FIRST STREET, SUITE 1820, CAMBRIDGE MA 02142